We collaborate with the world for the health of everyone in it.

Learn more

At the Janssen Pharmaceutical Companies of Johnson & Johnson, we envision a world without disease. To achieve this, we strive to couple our strong internal capabilities with the most compelling external science to transform how diseases are thought of being treated, cured, prevented and intercepted in the future.

Focus Areas

Our Pharmaceuticals business is divided into six core areas, Cardiovascular & Metabolism; Immunology; Infectious Diseases & Vaccines; Neuroscience; Oncology; and Pulmonary Hypertension. We seek innovation across all of these areas where there is significant unmet patient need.

CLICK a circle below to see the diseases we are targeting.
  • Metabolism, Retinal Diseases, Thrombosis
    Cardiovascular and Metabolism
    Cardiovascular and Metabolism
  • Gastroenterology, Rheumatology - IL-23 Pathway
  • Hepatitis, Respiratory Infections, Bacterial & Viral Vaccines
    Diseases and Vaccines
    Infectious Diseases and Vaccines
  • Mood Disorders, Neurodegenerative Disorders, Schizophrenia, Glutamatergic Pathway Diseases
  • Prostate Cancer, Solid Tumor Targeted Therapy, Immuno-Oncology, Hematologic Malignancies
  • Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
    Pulmonary Hypertension
    Pulmonary Hypertension

Collaboration Partners

Johnson & Johnson Innovation is comprised of a family of complementary teams that bring meaningful solutions and flexible approaches to support collaboration. From incubation facilities to early-stage investing – from venture funding to acquisition, our teams offer partners a full range of capabilities. 

Contact us

Make the Connection

We look forward to our first discussion. If you would like to discuss a collaboration,
please connect with us and we will schedule a call soon.



Neomed (Montreal)
7171 Frederick-Banting
Montreal, Quebec, CANADA H4S 1Z9
(514) 367 1212
Your web browser is out of date. For the most optimal experience, please upgrade to the newest version of IE. Thank You.